Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hamid Hassanzadeh

Orthopaedic Surgery Bethesda, MD Medical Doctor

NPI 1710140595 CMS profile 31776

6420 Rockledge Dr Ste 2200, Bethesda, MD 20817

Open in the dashboard

General payments

$1,090,764

444 records reported · program years 2019–2025

Research payments

$19,460

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$1,029,618

9 holdings reported · through program year 2025

Research they led as principal investigator

$804,511 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Hamid Hassanzadeh of Bethesda, MD is reported in the CMS Open Payments database as having received $1,090,764 across 444 general payments and $19,460 in research payments paid to them. Separately, studies naming them as principal investigator received $804,511 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,029,618 across 9 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

18 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369,051 46
2024 General $171,052 59
2023 General $132,768 71
2023 Research $780 1
2022 General $141,849 38
2022 Research $780 1
2021 General $110,943 55
2021 Research $13,500 5
2020 General $79,971 49
2020 Research $4,400 2
2019 General $85,130 126
2025 Ownership $70,322 1
2024 Ownership $206,370 2
2023 Ownership $516,672 2
2022 Ownership $62,815 1
2021 Ownership $60,315 1
2020 Ownership $57,815 1
2019 Ownership $55,308 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hamid Hassanzadeh
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Hamid Hassanzadeh were reported at $369,051. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Hamid Hassanzadeh Orthopaedic Surgery median Middle half National median
2019 $85,130 $644 $140–$2,844 $163
2020 $79,971 $312 $75–$1,860 $114
2021 $110,943 $520 $117–$2,495 $132
2022 $141,849 $598 $128–$2,731 $149
2023 $132,768 $461 $128–$2,264 $160
2024 $171,052 $497 $134–$2,475 $164
2025 $369,051 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $490,941 82 payments
  2. NuVasive, Inc. $442,013 207 payments
  3. Orthofix Medical, Inc. $41,407 39 payments
  4. Medtronic USA, Inc. $35,420 31 payments
  5. SurGenTec $33,300 1 payment
  6. Stryker Corporation $18,191 13 payments
  7. Medical Device Business Services, Inc. $14,274 11 payments
  8. Medtronic, Inc. $6,230 26 payments
  9. Alphatec Spine, Inc $2,629 14 payments
  10. Prosidyan, Inc $1,777 2 payments
  11. Other $4,582 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $686,116 89 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $286,966 9 payments
  3. Travel and Lodging $91,203 174 payments
  4. Food and Beverage $15,370 166 payments
  5. Royalty or License $6,368 3 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,200 1 payment
  7. Grant $1,500 1 payment
  8. Entertainment $41 1 payment
Products named General payments · program years 2019–2025
  1. XLIF Spine/Spine Surgery $346,784 27 payments
  2. RELINE Spine/Spine Surgery $82,267 77 payments
  3. EXCELSIUS GPS $52,314 7 payments
  4. Pulse $32,974 31 payments
  5. VERTEX $24,523 10 payments
  6. RELINE Spine/Spine Surgery $21,286 33 payments
  7. XLIF Spine/Spine Surgery $20,708 24 payments
  8. MONTEREY AL $15,750 1 payment
  9. EXPEDIUM $12,047 10 payments
  10. NAVIGATION $10,823 2 payments
  11. Other $137,601 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Orthofix Medical, Inc. $11,900 4 payments
  2. Pfizer Inc. $7,560 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

29

Median for Orthopedic Surgery: 203

Drug cost

$192

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 29 $192

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$412,945

Medicare's payments for the services billed

Medicare patients

751

Average age 74

Services billed

2,139

454 women, 297 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Osteoporosis 30%
Diabetes 27%
Ischemic heart disease 26%
Depression 24%
Chronic kidney disease 23%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

453 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record